ClinicalTrials.gg
CompletedNCT05429177Updated Sep 25, 2023

A First-in-Human Study of QY101 Ointment in Adult Subjects

A Phase 1 interventional study of QY101 ointment or vehicle in Healthy Volunteer, sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-25.

Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a phase I, randomized, double-blind, vehicle-controlled,single and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of QY101 ointment in Chinese healthy subjects

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects were fully aware of the purpose, nature, methods and possible adverse reactions of the trial, volunteered as subjects, and signed an form before the start of any research process.
  2. Male and female subjects aged 18 to 45 (including 18 and 45).
  3. Male weight≥50.0 kg, female weight≥45.0 kg; is in the range of 19.0 \~ 26.0 kg/ m2 (including the critical value).
  4. The subjects had no history of chronic or serious diseases such as cardiovascular, liver, kidney, respiration, blood and lymph, endocrine, immune, mental, nervous, gastrointestinal system, and were in good health.
  5. Physical examination, vital signs, clinical laboratory examination values (blood routine, urine routine, blood biochemistry, blood coagulation function, stool routine and occult blood, pregnancy test (female), hepatitis, , syphilis), 12-lead , chest X-ray examination, abdominal ultrasound examination results are all within the normal range or abnormalities with no clinical significance.
  6. The subjects (including male subjects) had no fertility plan, voluntary use of effective and no plan to donate sperm or eggs during the screening period and within 6 months after the end of the last administration.
  7. The subjects were able to communicate well with the researchers and understand and comply with the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution, such as a history of allergy to two or more drugs and food, or those known to be allergic to QY101 and .
  2. Screen those who have undergone surgery within the previous 3 months, or who plan to undergo surgery during the study period, or who have undergone surgery that will affect the absorption, distribution, metabolism and excretion of drugs.
  3. Diseases that need to be excluded with abnormal clinical manifestations, including, but not limited to, diseases of the nervous system, cardiovascular system, blood and lymphoid system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolic and skeletal system, etc.
  4. Subjects who cannot tolerate venipuncture, have a history of dizzy needles and blood sickness.
  5. Subjects with a history of severe skin disease (subject to the judgment of the researcher).
  6. Live (attenuated) vaccine was vaccinated within 2 months before screening.
  7. Smoking or drinking within 3 months before screening (smoking: > 10 cigarettes per day; drinking: > 15g pure alcohol per day, equivalent to 450mL beer, 150mL wine or 50mL low alcohol), or positive for nicotine, alcohol, abuse drugs (morphine / methamphetamine / ketamine / dimethylene dioxyamphetamine / tetrahydrocannabinic acid).
  8. Screen subjects who have participated in other drug clinical trials or have not come to participate in clinical trials within the first 3 months.
  9. Non-physiological blood loss ≥ 200ml within 3 months before screening (including trauma, blood collection, blood donation), or plan to donate blood during the study period or within 1 month after the end of the study.
  10. The subjects (female) are lactating.
  11. Strong inhibitors or inducers of liver metabolic enzymes were used in the previous 2 weeks (see Appendix 2 for details), or any drugs, including prescription, over-the-counter and herbal medicines, were used for oral or topical use, except vitamins and / or paracetamol.
  12. To screen subjects who drank too much tea, coffee and / or caffeinated beverages (more than 8 cups, 1 cup = 250mL) every day for the first 3 months.
  13. Subjects with abnormal vital signs were included in the standard reference range (including critical value): sitting systolic blood pressure 90\~139mmHg, diastolic blood pressure 55-89mmHg, pulse 55-100bpm, body temperature 36.037.4C, breathing 12-22bpm; if the subject's first examination result is abnormal, retest can be carried out after rest.
  14. There are tattoos, birthmarks, sunburns, abrasions, ulcers, erythema, dryness, scabs and scars in the target area (back, abdomen and lower limbs from thigh to calf) of the subjects.
  15. Subjects determined by other researchers to be unfit to participate.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    SAD Cohort 1(0.1% QY101 ointment or vehicle apply to 5%BSA)

    3 subjects use 0.1% QY101 ointment,1 subject uses vehicle topical applied to 5% Body Surface Area,assessed until 72 hours postdose

    Drug: QY101 ointment or vehicle

  • Experimental
    SAD Cohort 2(0.1% QY101 ointment or vehicle apply to 20%BSA)

    6 subjects use 0.1% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose

    Drug: QY101 ointment or vehicle

  • Experimental
    SAD Cohort 3(0.3% QY101 ointment or vehicle apply to 20%BSA)

    6 subjects use 0.3% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose

    Drug: QY101 ointment or vehicle

  • Experimental
    SAD Cohort 4(0.5% QY101 ointment or vehicle apply to 20%BSA)

    6 subjects use 0.5% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose

    Drug: QY101 ointment or vehicle

  • Experimental
    SAD Cohort 5(1.0% QY101 ointment or vehicle apply to 20%BSA)

    6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose

    Drug: QY101 ointment or vehicle

  • Experimental
    SAD Cohort 6(1.0% QY101 ointment or vehicle apply to 40%BSA)

    6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 40% Body Surface Area,assessed until 72 hours postdose

    Drug: QY101 ointment or vehicle

  • Experimental
    MAD Cohort 7(0.3% QY101 ointment or vehicle apply to 20%BSA)

    6 subjects use 0.3% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,twice daily for 7 days and once in the morning on D8

    Drug: QY101 ointment or vehicle

  • Experimental
    MAD Cohort 8(0.5% QY101 ointment or vehicle apply to 20%BSA)

    6 subjects use 0.5% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,twice daily for 7 days and once in the morning on D8

    Drug: QY101 ointment or vehicle

  • Experimental
    MAD Cohort 9(1.0% QY101 ointment or vehicle apply to 20%BSA)

    6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,twice daily for 7 days and once in the morning on D8

    Drug: QY101 ointment or vehicle

  • Experimental
    MAD Cohort 10(1.0% QY101 ointment or vehicle apply to 40%BSA)

    6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 40% Body Surface Area,twice daily for 7 days and once in the morning on D8

    Drug: QY101 ointment or vehicle

Interventions

  • DrugQY101 ointment or vehicle

    QY101 ointment or vehicl topical applied to skin

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: SAD:Day1 to Day18;MAD:Day1 to Day25

  2. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: SAD:Screening period and Day4;MAD:Screening period, Day5 and Day11

  3. Number of Participants With Clinically Significant Changes Form Baseline in Vital Signs

    Time frame: SAD:Screening period and Day1 to Day4;MAD:Screening period and Day1 to Day11

  4. Severity of local skin irritation

    Skin irritation response assessment recording method: -: no reaction; + (mild): only erythema can be observed; + (moderate): moderate erythema, edema; + (severe): severe erythema, edema with papules, vesicles; + (severe): severe erythema, edema, bullae, and even necrosis.

    Time frame: SAD:Day1 to Day4;MAD:Day1 to Day11

  5. Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings

    Time frame: SAD:Screening period and Day4;MAD:Screening period, Day5 and Day11

  6. Number of Participants With Clinically Significant Changes Form Baseline in Physical Examination

    Time frame: SAD:Screening period and Day4;MAD:Screening period, Day5 and Day11

Secondary outcomes

  1. Tmax of QY101

    Time of maximum concentration

    Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11

  2. Cmax of QY101

    Maximum observed plasma concentration

    Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11

  3. t1/2 of QY101

    The time it takes for the blood concentration of the drug to drop by half from the highest value in the body

    Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11

  4. AUC0-∞ of QY101

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration

    Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11

07

Study locations

1 site
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 23, 2022
StartActual
Jun 8, 2022
Primary completionActual
Jun 21, 2023
CompletionActual
Jun 21, 2023
Last update
Sep 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05429177
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Jun 8, 2022
Primary completion
Jun 21, 2023
Completion
Jun 21, 2023
Last update
Sep 25, 2023

Study contacts

zourong ruan
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion